You are here

psoriasis

J&J's Tremfya approved, further crowding IL-inhibitor market

J&J's Tremfya approved, further crowding IL-inhibitor market

BioPharma Dive

Interleukin-inhibitors

Flag link:

FDA clears Philips' light therapy wearable for mild psoriasis

FDA clears Philips' light therapy wearable for mild psoriasis

Fierce Biotech

Flag link:

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

Endpoints

Flag link:

Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?

Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?

Motley Fool

Valeant Pharmaceuticals

Flag link:

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Endpoints

Valeant Pharmaceuticals

Flag link:

How a $37,000-a-year medicine sets a good model for drug pricing

How a $37,000-a-year medicine sets a good model for drug pricing

Stat

Flag link:

Merck, Avillion ink development deal for nanobody psoriasis treatment

Merck, Avillion ink development deal for nanobody psoriasis treatment

Mass Device

Flag link:

Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016

Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016

Market Realist

Flag link:

J&J looks for the inside story with new online psoriasis campaign

J&J looks for the inside story with new online psoriasis campaign

Fierce Pharma

Flag link:

Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med

Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med

Fierce Pharma

Valeant Pharmaceuticals

Flag link:

Does Valeant have the ad dollars to keep Siliq competitive in psoriasis?

Does Valeant have the ad dollars to keep Siliq competitive in psoriasis?

Fierce Pharma

Valeant Pharmaceuticals

Flag link:

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab

Endpoints

Flag link:

Purdue Pharma Puts Skin In The Game With Psoriasis Deal

Purdue Pharma Puts Skin In The Game With Psoriasis Deal

Seeking Alpha

Flag link:

Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?

Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?

Fierce Pharma

DTC advertising

Flag link:

FDA OKs Expanded Use of Amgen's Enbrel

FDA OKs Expanded Use of Amgen's Enbrel

Investopedia

Flag link:

Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead

Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead

Fierce Pharma

Flag link:

This Looks to Be Johnson & Johnson's Next Blockbuster Drug

This Looks to Be Johnson & Johnson's Next Blockbuster Drug

Motley Fool

Flag link:

J&J psoriasis drug tops placebo, Humira in late stage study

J&J psoriasis drug tops placebo, Humira in late stage study

Yahoo/Reuters

Flag link:

Celgene's Otezla Is A Big Hit

Celgene's Otezla Is A Big Hit

Motley Fool

Flag link:

Valeant gets FDA panel recommendation for psoriasis drug

Valeant gets FDA panel recommendation for psoriasis drug

Marketwatch

Valeant Pharmaceutcals

advisory panels

Flag link: